‹ News

Free examples from this scan SYRE LASR ANRO DELL CIEN BCRX DSGN CAVA GTE XRPC

ANRO: Ascending Triangle detected on 17 Mar 2026

All prices, scores, and news on this page reflect data available before market open on 17 Mar 2026.

Free example: 1 of 46 setups from the 17 Mar 2026 scan. Subscribers get the full list every trading day by 6 AM ET.

Browse all free Ascending Triangle examples →

On 17 Mar 2026, our scan flagged ANRO as a ascending triangle setup scoring 88 out of 98 (Strong tier), with a 75% win probability based on our historical pattern database and a 0.55 to 1 risk to reward profile from the published levels. This is a swing trade setup: win probability reflects a multi-day swing hold, not an intraday move. At $24.29, the conservative target is $25.51 with a stop at $22.08.

Overall Score

88 of 98

Strong

Win Probability

75%

High

Trade R:R

0.55 : 1

$1.22 to target $2.21 to stop

Summary Context Technical Indicators

Swing Trading Plan

Entry

$24.29

Target

$25.51

Stop Loss

$22.08

Holding Period

1-7 trading days

Expected Return

+$0.50

Exp. Reward

+$0.73

Exp. Risk

-$0.23

Expected figures are probability-weighted from our historical pattern database; Trade R:R is measured from the entry, target and stop levels.

Current Setup

Alto reported full-year 2025 results on March 16, 2026, catalyzing a strong technical setup. ANRO has formed an ascending triangle from consolidation, with the current price at $24.29 sitting just above key resistance at $23.95 and well above support at $20.46. The structure score of 15.0/15 reflects textbook triangle geometry. Volume is exceptional at 792,466 shares (3.14x average), providing strong breakout confirmation. Breakout score of 13.0/13 indicates imminent upside potential. Overall score of 87.6/98 signals high-quality pattern with 74.57% win probability. RSI at 68.08 is elevated but not yet overbought.

Stock Context

Alto announced a $120 million private placement financing on March 16, 2026, led by Commodore Capital with participation from new and existing biotech investors. After giving effect to the net proceeds, the company estimates cash and cash equivalents would have been approximately $275 million as of February 28, 2026. ALTO-207 Phase 2b initiation is expected in H1 2026 and ALTO-101 topline data is expected around end of Q1 2026. BTIG Research lifted price target to $28.00 with buy rating on February 17, and Chardan Capital boosted target to $30.00 with buy rating on January 5. Six analysts rate Buy, one Hold, one Sell. The financing and institutional backing validate pipeline strategy.

What to Expect

An ascending triangle breakout above $23.95 resistance, with conservative target at $25.51 (+5.1% from current), is supported by the 74.57% win probability. Historical data suggests measured moves could extend toward $28-30 based on analyst price targets and pattern geometry. Volume needs to sustain above 250k-300k daily average for confirmation. Invalidation occurs at support breakdown below $20.46, which would negate the bullish structure. RSI expansion beyond 75 would signal strength; failure to close above resistance on this attempt indicates triangle failure.

Risk Factors

Sell-side analysts predict full-year 2026 EPS of -2.54, underscoring ongoing cash burn despite extended runway. ALTO-101 Phase 2 data expected end of Q1 2026 — trial failure would trigger sharp selloff. Weiss Ratings maintains sell (e+) rating as of December 29. Beta of 1.34 creates amplified downside on sector weakness. Volatility at 97.1% is elevated; 47.75% one-month gain creates technical exhaustion risk. Pattern is post-catalyst (financing announcement), so momentum may fade if Phase 2b or Phase 3 initiation delays materialize. Dilution from PIPE shares could pressure post-breakout momentum.

How We Find and Score This Setup

We scan more than 6,000 NYSE and NASDAQ stocks every trading day and compare each detected pattern against a database of 370,000+ historical detections. Every setup is scored across three dimensions: Structure, Volume, and Breakout Readiness. Win probability is a calibrated estimate of how similar historical setups performed over the following 10 trading days. This is a swing trading tool built for multi-day holds. It is not built or tested for day trading.

Frequently Asked Questions

Is ANRO a good swing trade?

ANRO scored 88 out of 98 on our ascending triangle scan, with a 75% historical win probability over a 1-7 trading days hold. Strong setup based on our systematic scoring.

What is the entry, target, and stop loss for this setup?

The setup's reference price is $24.29, with a conservative target of $25.51 and a stop loss at $22.08.

What would invalidate this ascending triangle setup?

A close below the stop loss at $22.08 would invalidate the setup and suggest the pattern has failed.

How is the win probability calculated?

Win probability is a calibrated estimate of how similar historical ascending triangle setups performed over the following 10 trading days, drawn from a database of 370,000+ historical pattern detections across 6,000+ NYSE and NASDAQ stocks.

Market & Sector Regime

Market

Neutral -0.18

-1.0 0 +1.0

Health Care Sector

Neutral -0.18

-1.0 0 +1.0

Other Patterns Detected Today

Bull Flag

65 days in pattern

Weak 25.2

Overall Score

38 of 40

Exceptional

Pattern Quality

20 of 20

Exceptional

Setup

13 of 20

Moderate

R/R

17 of 18

Exceptional

Context

Pattern Quality Score

15 of 15

Exceptional

Structure

13 of 13

Exceptional

Breakout

10 of 12

Strong

Volume

Recent Performance

+10.5%

+17.7%

+47.8%

+65.5%

Momentum & Trend

RSI (14)

68.1

Neutral

MACD Histogram

+0.25

Bullish

Bollinger Band Position

105.7%

Upper Band

Volatility & Risk

20-Day Volatility

0.97

Very High

ATR %

7.7%

High

Beta

1.34

Above Mkt

Volume Analysis

Volume Ratio

3.14x

Very High

20-Day Avg Vol

252K

shares / day

Current Volume

792K

shares traded

Price Levels

Target

$25.51

52W High

$25.12

Current

$24.29

Resistance

$23.95

Stop Loss

$22.08

Support

$20.46

52W Low

$1.60

Disclaimer: This analysis is algorithmically generated for educational purposes only and does not constitute financial advice. Past pattern performance does not guarantee future results. Win probabilities are based on historical data across 370,000+ observations. Always conduct your own research and consult a qualified financial advisor. AI-assisted contextual analysis by Claude (Anthropic). Indicators reflect values at time of detection.